Drug Research
Long-Awaited Daxxify By Revance Will Compete With Botox
Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by the name of the firm. Daxxify, Revance's long-awaited Botox rival, has officially received FDA approval,...
Drug Research
Introduction of Anti-Evolocumab Antibodies From Bio-Rad
A group of type 1 antibodies recently made available by Bio-Rad Laboratories are intended to prevent the drug evolcumab from attaching to its target, human proprotein convertase subtilisin/kexin type 9. (PCSK9). These recombinant, sequence-defined antibodies are meant to create...
Drug Research
Merck Assesses 5 Years of Keytruda Lung Cancer Research
By demonstrating a massive survival benefit, Keytruda's Keynote-189 study precipitated a turning point in the development of lung cancer medications. Merck & Co. is now providing a five-year review of the data that rendered the PD-1 inhibitor the norm...
Drug Research
Modus Therapeutics Enrols First Patient To Explore Sevuparin
The treatment for paediatric patients with severe malaria is being evaluated through research.
The first patient has been enrolled in the SEVUSMART study, according to a statement from Modus Therapeutics, a firm that creates therapies for individuals who have significant unmet...
Drug Research
Non-Viral CRISPR May Potentially Boost Cell And Gene Therapy
A new variation of the CRISPR-Cas9 gene editing system, according to researchers from the Gladstone Institutes and University of California San Francisco (UCSF), enables the introduction of particularly long DNA sequences to specific locations in the genomes of cells...
Drug Research
Moderna Sues Pfizer, BioNTech Over mRNA COVID-19 Vaccines
According to complaints filed by Moderna, Pfizer and BioNTech's COVID-19 vaccine Comirnaty® violates patents the company filed between 2010 and 2016 that protect its core messenger RNA (mRNA) technology.
Both the Regional Court of Düsseldorf in Germany and the United...
Drug Research
Formulation Development Offshore Market To Be $60bn By 2030
A recent study predicts that the size of the global formulation development outsourcing market will increase from its value of $35.1 billion in 2022 to $61.4 billion by 2030, growing at a CAGR of 7.2%.
The researchers discovered that the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read